These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 17511934)

  • 21. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
    Shin JU; Park JH; Cho BC; Lee JH
    Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cetuximab-induced crusted pustular eruption with patchy alopecia.
    Fischer R; Blackmon J; Rajpara A
    Dermatol Online J; 2014 Oct; 20(10):. PubMed ID: 25526010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cetuximab-associated pulmonary toxicity.
    Chua W; Peters M; Loneragan R; Clarke S
    Clin Colorectal Cancer; 2009 Apr; 8(2):118-20. PubMed ID: 19739274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
    Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
    Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The management of EGFR inhibitor adverse events: a case series and treatment paradigm.
    Wnorowski AM; de Souza A; Chachoua A; Cohen DE
    Int J Dermatol; 2012 Feb; 51(2):223-32. PubMed ID: 22250636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors.
    Gerber PA; Kukova G; Buhren BA; Homey B
    Dermatology; 2011; 222(2):144-7. PubMed ID: 21346311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Acneiform eruptions induced by cetuximab].
    Walon L; Gilbeau C; Lachapelle JM
    Ann Dermatol Venereol; 2003 Apr; 130(4):443-6. PubMed ID: 12843857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.
    Lacouture ME; Melosky BL
    Skin Therapy Lett; 2007; 12(6):1-5. PubMed ID: 17762902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erlotinib induced target-like purpura.
    Rungtrakulchai R; Rerknimitr P
    Dermatol Online J; 2014 Feb; 20(2):. PubMed ID: 24612572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
    Bodet D; Bartralot R; Mollet J; Heras C; García-Patos V
    Actas Dermosifiliogr; 2006 Mar; 97(2):148-9. PubMed ID: 16595122
    [No Abstract]   [Full Text] [Related]  

  • 31. Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
    Dunsford J
    Clin J Oncol Nurs; 2008 Jun; 12(3):405-7. PubMed ID: 18515238
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
    Mitchell EP; Perez-Soler R; Van Cutsem E; Lacouture ME
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
    Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
    Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
    Ong CK; Tan WC; Chan LC; Abdul Razak M
    Med J Malaysia; 2012 Apr; 67(2):222-3. PubMed ID: 22822651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cutaneous side effects of EGF receptor inhibitors].
    Nassar D; Soutou B; Aractingi S
    Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rosaceiform eruption induced by cetuximab.
    Fernández-Torres R; Martínez Gomez W; Cuevas Santos J; Paradela S; Fonseca Capdevila E
    Eur J Dermatol; 2010; 20(3):392-3. PubMed ID: 20172848
    [No Abstract]   [Full Text] [Related]  

  • 37. Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients.
    Santiago F; Gonçalo M; Reis JP; Figueiredo A
    An Bras Dermatol; 2011; 86(3):483-90. PubMed ID: 21738965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Iyer R; Bharthuar A
    Expert Opin Pharmacother; 2010 Feb; 11(2):311-20. PubMed ID: 20088749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR inhibition in NSCLC: the emerging role of cetuximab.
    Herbst RS
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S41-51. PubMed ID: 19780245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cutaneous side effects of EGF-receptor inhibition and their management].
    Gutzmer R; Werfel T; Kapp A; Elsner J
    Hautarzt; 2006 Jun; 57(6):509-13. PubMed ID: 16205868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.